A double-blind, placebo-controlled, randomized, parallel-group study to evaluate the effects of vildagliptin on the maximum insulin secretion in patients with type 2 diabetes mellitus.
Phase of Trial: Phase III
Latest Information Update: 04 May 2012
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Novartis
- 04 May 2012 Actual end date (1 Sep 2005) added as reported by ClinicalTrials.gov.
- 20 Nov 2006 New trial record.